Dr. Olson's clinical efforts focus on pediatric hematopoietic stem cell transplantation (HSCT), with a specific emphasis on HSCT for patients with inherited and acquired bone marrow failure.
Timothy Olson, MD, PhD
Daria Babushok, MD, PhD
Dr Daria Babushok is a physician-scientist and an Assistant Professor of Medicine in the Division of Hematology-Oncology at the University of Pennsylvania. Dr Babushok laboratory conducts basic and translational research focusing on the immune pathogenesis of acquired aplastic anemia and the development of clonal hematopoiesis in acquired aplastic anemia and other bone marrow failure disorders.
Ben received his Bachelor of Science degree in Chemistry from Haverford College in 2019. Before becoming a Research Specialist, Ben worked in the Comprehensive Bone Marrow Failure Center as an undergraduate, and he wrote one of his undergraduate theses on research related to acquired aplastic anemia. The scope of his research has since broadened to include other bone marrow failure disorders such as paroxysmal nocturnal hemoglobinuria.
The long-term goal of the Babushok Laboratory to improve the outcomes of patients with bone marrow failure disorders through bench-to-bedside research aimed at elucidating mechanisms of hematopoietic failure and transforming this knowledge into rational therapies.
- The role of germline genetic predisposition syndromes in the development of pediatric myelodysplastic syndrome and acute myeloid leukemia
- Patterns of HLA allele expression and clonal evolution in acquired aplastic anemia, and how these findings may serve as biomarkers for disease response as well as clues to the underlying immune basis of this disease
- Investigation of how intrinsic pathways governing hematopoietic stem cell niche function can be harnessed to improve the efficiency and durability of donor engraftment after hematopoietic stem cell transplantation, particularly in the context of bone marrow failure syndromes.
- Clinical trials of novel conditioning and T cell depletion strategies to improve survival and decrease allo-immune complications for patients with non-malignant hematologic disorders undergoing hematopoietic stem cell transplantation.